Chen Kong, Kolls Jay K
Richard King Mellon Foundation Institute for Pediatric Research, Children's Hospital of Pittsburgh, Pittsburgh, PA, United States.
Richard King Mellon Foundation Institute for Pediatric Research, Children's Hospital of Pittsburgh, Pittsburgh, PA, United States.
Gene. 2017 May 30;614:8-14. doi: 10.1016/j.gene.2017.01.016. Epub 2017 Jan 22.
The discovery of the key roles of interleukin-17A (IL-17A) and IL-17A producing cells in inflammation, autoimmune diseases and host defense has led to the experimental targeting of the IL-17A pathway in animal models of diseases as well as in clinical trials in humans. These therapeutic agents include biological products that target IL-17A and IL-23, an upstream regulator of IL-17A production. IL-17A producing T helper cells (Th17 cells) are a distinct lineage from the Th1 and Th2 CD4+ lineages and have been suggested to represent a good drug target in certain inflammatory conditions. Targeting IL-17A has been proven to be a good approach as anti-IL-17A is FDA approved for the treatment of psoriasis in 2015. In host defense, IL-17A has been shown to be mostly beneficial against infection caused by extracellular bacteria and fungi. This review will overview the discovery of IL-17A, the receptors used by this cytokine and its role in mucosal immunity and inflammation.
白细胞介素-17A（IL-17A）及产生IL-17A的细胞在炎症、自身免疫性疾病和宿主防御中的关键作用已被发现，这促使人们在疾病动物模型以及人类临床试验中对IL-17A通路进行实验性靶向治疗。这些治疗药物包括靶向IL-17A和IL-23（IL-17A产生的上游调节因子）的生物制品。产生IL-17A的辅助性T细胞（Th17细胞）是与Th1和Th2 CD4+谱系不同的谱系，并且在某些炎症情况下被认为是一个良好的药物靶点。靶向IL-17A已被证明是一种有效的方法，因为抗IL-17A于2015年被美国食品药品监督管理局（FDA）批准用于治疗银屑病。在宿主防御中，IL-17A已被证明对抵御由细胞外细菌和真菌引起的感染大多有益。本综述将概述IL-17A的发现、该细胞因子所使用的受体及其在黏膜免疫和炎症中的作用。
